# A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers

> **NCT01943864** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 20 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Trametinib (single tablet)
- **DRUG:** Trametinib (Multiple tablet)

## Key facts

- **NCT ID:** NCT01943864
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-19
- **Primary completion:** 2014-07-01
- **Final completion:** 2016-02-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01943864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01943864, "A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01943864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*